| Code | CSB-RA858415MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to SAL-023, targeting sclerostin (SOST), a glycoprotein secreted primarily by osteocytes in bone tissue. SOST functions as a negative regulator of bone formation by inhibiting the Wnt signaling pathway, which is essential for osteoblast differentiation and bone mineralization. By binding to LRP5/6 co-receptors, sclerostin prevents Wnt ligand interaction, thereby suppressing bone formation. Dysregulation of SOST expression is associated with various skeletal disorders, including osteoporosis, sclerosteosis, and van Buchem disease, making it a significant therapeutic target for bone-related conditions.
SAL-023 represents a research-grade reference antibody used in investigating sclerostin biology and its role in bone metabolism. This biosimilar provides researchers with a reliable tool for studying SOST-mediated mechanisms in skeletal homeostasis, bone remodeling processes, and potential therapeutic interventions for metabolic bone diseases. The antibody supports investigations into Wnt pathway modulation and osteoblast function, facilitating advances in understanding bone formation and regeneration at the molecular level.
There are currently no reviews for this product.